Puri 2013.

Trial name or title	A randomized phase 2 trial of pemetrexed (P) and gefitinib (G) versus G as first‐line treatment for patients with stage IV non‐squamous (NS) non‐small cell lung cancer (NSCLC) with activating epidermal growth factor receptor (EGFR) mutations
Methods	Randomised
Participants	Stage IV NS NSCLC, an Eastern Cooperative Oncology Group performance status (ECOG PS) of 0 to 1 and an activating EGFR mutation
Interventions	Gefitinib versus pemetrexed
Outcomes	PFS Time to progressive disease OS ORR DCR Adverse events
Starting date	Not known
Contact information	Not known
Notes	—

AUC: Area under curve
 C: carboplatin
 DCR: disease control rate
 ECOG: Eastern Cooperative Oncology Group
 ECOG PS: ECOG Performance Status
 EGFR: epidermal growth factor receptor
 G: gefitinib
 NSCLC: non‐small cell lung cancer
 ORR: overall response rate
 OS: overall survival
 P: paclitaxel
 PC: pemetrexed‐cisplatin
 PFS: progression‐free survival
 TXT: first‐line treatment